EP
HUMA icon

Essential Partners’s Humacyte HUMA Stock Holding History

Essential Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197 Sell
252
-15,756
-98% -$14.6K ﹤0.01% 2638
2026
Q1 		$9.71K Buy
+16,008
New +$16.6K ﹤0.01% 1269
2025
Q4 		– Sell
-267
Closed -$465 – 2836
2025
Q3 		$465 Sell
267
-714
-73% -$1.4K ﹤0.01% 2223
2025
Q2 		$2.05K Buy
+981
New +$1.89K ﹤0.01% 1314

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Essential Partners's HUMA Position: Q2 2026 in Review

Essential Partners reduced its Humacyte (HUMA) stake by 98% in Q2 2026, selling an estimated $14.6K and leaving 252 shares worth $197. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

Essential Partners first reported a position in HUMA in Q2 2025 and has held it in 4 quarters since. The position peaked at $9.71K in Q1 2026. 162 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Essential Partners held 252 shares of Humacyte worth $197 as of Q2 2026.
  • Essential Partners sold 15,756 Humacyte shares in Q2 2026, an estimated $14.6K.
  • Humacyte made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2638 holding.
  • Essential Partners first reported a position in Humacyte in Q2 2025 and has held it in 4 quarters since.
  • Essential Partners's Humacyte position peaked at $9.71K in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.